Advancing Clinical Research of Gene Therapies in Brazil

Held December 2, 2020, 2-6 p.m. BRT


This event is in partnership between ASGCT and the Brazilian Association of Cellular and Gene Therapy. The goal of this program is for speakers with experience in clinical development to share their experiences and insights on factors to consider to successfully initiate clinical trials of in vivo and ex vivo gene therapies in Brazil. Stimulating such additional clinical research is an important step in expanding availability and access to these therapies for patients in need in the area.

Agenda

Opening Remarks

Kenneth Cornetta, M.D. 

Indiana University  
Chair, Global Outreach Committee, ASGCT 

Sang W. Han, Ph.D. 

Universidade Federal de São Paulo 
Vice President, ABTCEL-GEN 

Developing Clinical Trials for Hematological Cancers with CAR T-cell Therapy 

Renato Cunha, M.D., Ph.D.  

Ribeirão Preto Medical School - São Paulo University 
Getting CAR T-cell therapy for leukemia into clinical trials in Brazil: Challenges and opportunities 

Richard C. Koya, M.D., Ph.D. 

Roswell Park Comprehensive Cancer Center 
Considerations for developing genetically modified T-cell therapy trials 

Developing Gene Therapy Clinical Trials for Monogenic Diseases 

Temis Maria Felix, Ph.D. 

Medical Genetics Service of Hospital de Clínicas de Porto Alegre 
Epidemiology of monogenic disorders in Brazil 

Margareth Castro Ozelo, M.D., Ph.D. 

WFH International Haemophilia Training Centre at the University of Campinas 
Getting gene therapy for hemophilia into clinical trials in Brazil: Challenges and opportunities
  

Punam Malik, M.D. 

Cincinnati Children's Hospital Medical Center 
Considerations for early clinical trials on gene transfer 

Maritza McIntyre, Ph.D. 

StrideBio 
Regulatory considerations for early gene therapy trials 

 

Annual Meeting

The Annual Meeting provides an international forum where the latest gene and cell therapy developments are presented and critically discussed. ASGCT's annual meeting brings together more than 3,400 professionals including scientists, physicians, and patient advocates.

Policy Summit

ASGCT's Policy Summit focuses on key policy challenges and opportunities in the development of, access to, and responsible use of gene and cell therapies, including manufacturing, clinical trial design, evidence generation, and payment policy. Diverse new topics in 2020 will include market access in the EU, newborn screening policies, and non-therapeutic uses of gene editing.

2021

ASGCT 24th Annual Meeting

May 11-14, 2021